The prospect of induced pluripotent stem cells for diabetes mellitus treatment

Therapeutic Advances in Endocrinology and Metabolism

Volumn 2, Issue 5, 2011, Pages 197-210

  Soejitno, Andreas ^a   Prayudi, Pande Kadek Aditya ^a  

^a UDAYANA UNIVERSITY   (Indonesia)

Author keywords

cellular reprogramming; diabetes mellitus; induced pluripotent stem (iPS) cells; pancreatic cells

Indexed keywords

ALGINIC ACID; AZACITIDINE; BONE MORPHOGENETIC PROTEIN 4; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; EXENDIN 4; FIBROBLAST GROWTH FACTOR 2; GLUCOCORTICOID; NICOTINAMIDE; RAPAMYCIN; TACROLIMUS; VALPROIC ACID;

ANTIGENICITY; AUTOIMMUNITY; CELL ACTIVITY; CELL DESTRUCTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELLULAR REPROGRAMMING; DIABETES MELLITUS; DYSLIPIDEMIA; EPIGENETICS; GENETIC ENGINEERING; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOPENIA; LYMPHOMA; MICROENCAPSULATION; NEPHROTOXICITY; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 83755179136     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018811420198     Document Type: Review

References (92)

1. Aasen T. Raya A. Barrero M.J. Garreta E. Consiglio A. Gonzalez F. et al (2008) Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26: 1276–1284.
2. Aguayo-Mazzucato C. Bonner-Weir S. (2010) Stem cell therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 6: 139–148.
3. Alexander S.I. Smith N. Hu M. Verran D. Shun A. Dorney S. et al (2008) Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 358: 369–374.
4. Ali M.A. Dayan C.M. (2009) The importance of residual endogenous beta-cell preservation in type 1 diabetes. Br J Diabetes Vasc Dis 9: 6–6.
5. Alipio Z. Liao W. Roemer E.J. Waner M. Fink L.M. Ward D.C. et al (2010) Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic β-like cells. Proc Natl Acad Sci 107: 13426–13431.
6. Anastasia L. Pelissero G. Venerando B. Tettamanti G. (2010) Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. Cell Death Differ 17: 1230–1237.
7. Anderson G. Lane P.J. Jenkinson E.J. (2007) Generating intrathymic microenvironments to establish T-cell tolerance. Nat Rev Immunol 7: 954–963.
8. Assady S. Maor G. Amit M. Itskovitz-Eldor J. Skorecki K.L. Tzukerman M. (2001) Insulin production by human embryonic stem cells. Diabetes 50: 1691–1697.
9. Bernstein B.E. Meissner A. Lander E.S. (2007) The mammalian epigenome. Cell 128: 669–681.
10. Bernstein B.E. Mikkelsen T.S. Xie X. Kamal M. Huebert D.J. Cuff J. et al (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315–326.
11. Chen Z.Y. He C.Y. Ehrhardt A. Kay M.A. (2003) Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8: 495–500.
12. Chidgey A.P. Layton D. Trounson A. Boyd R.L. (2008) Tolerance strategies for stem-cell-based therapies. Nature 453: 330–337.
13. de Haan B.J. Faas M.M. de Vos P. (2003) Factors influencing insulin secretion from encapsulated islets. Cell Transplant 12: 617–625.
14. de Vos P. de Haan B.J. Wolters G.H. Strubbe J.H. van Schilfgaarde R. (1997) Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets. Diabetologia 40: 262–270.
15. de Vos P. Faas M.M. Strand B. Calafiore R. (2006) Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 27: 5603–5617.
16. de Vos P. Hamel A.F. Tatarkiewicz K. (2002) Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia 45: 159–173.
17. Derbinski J. Schulte A. Kyewski B. Klein L. (2001) Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2: 1032–1039.
18. Donati I. Holtan S. Morch Y.A. Borgogna M. Dentini M. Skjak-Braek G. (2005) New hypothesis on the role of alternating sequences in calcium-alginate gels. Biomacromolecules 6: 1031–1040.
19. Dusseault J. Tam S.K. Menard M. Polizu S. Jourdan G. Yahia L. et al (2006) Evaluation of alginate purification methods: effect on polyphenol, endotoxin, and protein contamination. J Biomed Mater Res A 76: 243–251.
20. Duvivier-Kali V.F. Omer A. Parent R.J. O'Neil J.J. Weir G.C. (2001) Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes 50: 1698–1705.
21. Efrat S. (2008) Beta-cell replacement for insulin-dependent diabetes mellitus. Adv Drug Deliv Rev 60: 114–123.
22. Eisenbarth G.S. (2007) Update in type 1 diabetes. J Clin Endocrinol Metab 92: 2403–2407.
23. Finegood D.T. Scaglia L. Bonner-Weir S. (1995) Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 44: 249–256.
24. Flores K.G. Li J. Sempowski G.D. Haynes B.F. Hale L.P. (1999) Analysis of the human thymic perivascular space during aging. J Clin Invest 104: 1031–1039.
25. Fritschy W.M. Wolters G.H. van Schilfgaarde R. (1991) Effect of alginate-polylysine-alginate microencapsulation on in vitro insulin release from rat pancreatic islets. Diabetes 40: 37–43.
26. Gabler J. Arnold J. Kyewski B. (2007) Promiscuous gene expression and the developmental dynamics of medullary thymic epithelial cells. Eur J Immunol 37: 3363–3372.
27. Gallwitz B. (2008) Managing the β-cell with GLP-1 in type 2 diabetes. Br J Diabetes Vasc Dis 8(Suppl 2): 7–7.
28. Gillespie K.M. (2006) Type 1 diabetes: pathogenesis and prevention. CMAJ 175: 165–170.
29. Halle J.P. Leblond F.A. Landry D. Fournier A. Chevalier S. (1992) Studies of 300-microns microcapsules: I. Use of arginine esterase release by microencapsulated prostatic cells as a measure of membrane permeability. Transplant Proc 24: 2930–2932.
30. Halle J.P. Leblond F.A. Pariseau J.F. Jutras P. Brabant M.J. Lepage Y. (1994) Studies on small (< 300 microns) microcapsules: II– Parameters governing the production of alginate beads by high voltage electrostatic pulses. Cell Transplant 3: 365–372.
31. Hochedlinger K. Plath K. (2009) Epigenetic reprogramming and induced pluripotency. Development 136: 509–523.
32. Hu B.Y. Weick J.P. Yu J. Ma L.X. Zhang X.Q. Thomson J.A. et al (2010) Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 107: 4335–4340.
33. Jia F. Wilson K.D. Sun N. Gupta D.M. Huang M. Li Z. et al (2010) A nonviral minicircle vector for deriving human iPS cells. Nat Methods 7: 197–199.
34. Joffre O. Santolaria T. Calise D. Al Saati T. Hudrisier D. Romagnoli P. et al (2008) Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 14: 88–92.
35. Kaji K. Norrby K. Paca A. Mileikovsky M. Mohseni P. Woltjen K. (2009) Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458: 771–775.
36. Kaufman D.S. Hanson E.T. Lewis R.L. Auerbach R. Thomson J.A. (2001) Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 98: 10716–10721.
37. Kim K. Doi A. Wen B. Ng K. Zhao R. Cahan P. et al (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467: 285–290.
38. King C. Davies J. Mueller R. Lee M.S. Krahl T. Yeung B. et al (1998) TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th 2 phenotype. Immunity 8: 601–613.
39. Kulseng B. Thu B. Espevik T. Skjak-Braek G. (1997) Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplant 6: 387–394.
40. Limbert C. Path G. Jakob F. Seufert J. (2008) Beta-cell replacement and regeneration: Strategies of cell-based therapy for type 1 diabetes mellitus. Diabetes Res Clin Pract 79: 389–399.
41. Lopez-Avalos M.D. Tatarkiewicz K. Sharma A. Bonner-Weir S. Weir G.C. (2001) Enhanced maturation of porcine neonatal pancreatic cell clusters with growth factors fails to improve transplantation outcome. Transplantation 71: 1154–1162.
42. Lowry W.E. Richter L. Yachechko R. Pyle A.D. Tchieu J. Sridharan R. et al (2008) Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 105: 2883–2888.
43. Maehr R. Chen S. Snitow M. Ludwig T. Yagasaki L. Goland R. et al (2009) Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A 106: 15768–15773.
44. Maherali N. Ahfeldt T. Rigamonti A. Utikal J. Cowan C. Hochedlinger K. (2008) A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3: 340–345.
45. Maherali N. Hochedlinger K. (2008) Induced pluripotency of mouse and human somatic cells. Cold Spring Harb Symp Quant Biol 73: 157–162.
46. Mali P. Ye Z. Hommond H.H. Yu X. Lin J. Chen G. et al (2008) Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 26: 1998–2005.
47. Martinez-Fernandez A. Nelson T.J. Yamada S. Reyes S. Alekseev A.E. Perez-Terzic C. et al (2009) iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res 105: 648–656.
48. Mikkelsen T.S. Hanna J. Zhang X. Ku M. Wernig M. Schorderet P. et al (2008) Dissecting direct reprogramming through integrative genomic analysis. Nature 454: 49–55.
49. Mikkelsen T.S. Ku M. Jaffe D.B. Issac B. Lieberman E. Giannoukos G. et al (2007) Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448: 553–560.
50. Miyara M. Sakaguchi S. (2007) Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13: 108–116.
51. Moretti A. Bellin M. Jung C.B. Thies T.-M. Takashima Y. Bernshausen A. et al (2010) Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J 24: 700–711.
52. Nakagawa M. Koyanagi M. Tanabe K. Takahashi K. Ichisaka T. Aoi T. et al (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotech 26: 101–106.
53. Narsinh K.H. Jia F. Robbins R.C. Kay M.A. Longaker M.T. Wu J.C. (2011) Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc 6: 78–88.
54. Nelson T.J. Martinez-Fernandez A. Yamada S. Perez-Terzic C. Ikeda Y. Terzic A. (2009) Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 120: 408–416.
55. Nichols J. Zevnik B. Anastassiadis K. Niwa H. Klewe-Nebenius D. Chambers I. et al (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95: 379–391.
56. Okamoto Y. Douek D.C. McFarland R.D. Koup R.A. (2002) Effects of exogenous interleukin-7 on human thymus function. Blood 99: 2851–2858.
57. Okita K. Hong H. Takahashi K. Yamanaka S. (2010) Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 5: 418–428.
58. Okita K. Ichisaka T. Yamanaka S. (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448: 313–317.
59. Okita K. Nakagawa M. Hyenjong H. Ichisaka T. Yamanaka S. (2008) Generation of mouse induced pluripotent stem cells without viral vectors. Science 322: 949–953.
60. Olmer R. Haase A. Merkert S. Cui W. Palecek J. Ran C. et al (2010) Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. Stem Cell Res 5: 51–64.
61. Omer A. Duvivier-Kali V. Fernandes J. Tchipashvili V. Colton C.K. Weir G.C. (2005) Long-term normoglycemia in rats receiving transplants with encapsulated islets. Transplantation 79: 52–58.
62. Park I.H. Zhao R. West J.A. Yabuuchi A. Huo H. Ince T.A. et al (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141–146.
63. Petruzzo P. Pibiri L. de Giudici M.A. Basta G. Calafiore R. Falorni A. et al (1991) Xenotransplantation of microencapsulated pancreatic islets contained in a vascular prosthesis: preliminary results. Transpl Int 4: 200–204.
64. Reik W. (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447: 425–432.
65. Roche E. Reig J.A. Campos A. Paredes B. Isaac J.R. Lim S. et al (2005) Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes. Transpl Immunol 15: 113–129.
66. Ryan E.A. Paty B.W. Senior P.A. Bigam D. Alfadhli E. Kneteman N.M. et al (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54: 2060–2069.
67. Sakaguchi S. Ono M. Setoguchi R. Yagi H. Hori S. Fehervari Z. et al (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8–27.
68. Sandler S. Andersson A. Eizirik D.L. Hellerstrom C. Espevik T. Kulseng B. et al (1997) Assessment of insulin secretion in vitro from microencapsulated fetal porcine islet-like cell clusters and rat, mouse, and human pancreatic islets. Transplantation 63: 1712–1718.
69. Soon-Shiong P. Feldman E. Nelson R. Heintz R. Merideth N. Sandford P. et al (1992) Long-term reversal of diabetes in the large animal model by encapsulated islet transplantation. Transplant Proc 24: 2946–2947.
70. Soria B. Roche E. Berna G. Leon-Quinto T. Reig J.A. Martin F. (2000) Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 49: 157–162.
71. Spence P.J. Green E.A. (2008) Foxp3+ regulatory T cells promiscuously accept thymic signals critical for their development. Proc Natl Acad Sci U S A 105: 973–978.
72. Stadtfeld M. Nagaya M. Utikal J. Weir G. Hochedlinger K. (2008) Induced pluripotent stem cells generated without viral integration. Science 322: 945–949.
73. Sutherland J.S. Goldberg G.L. Hammett M.V. Uldrich A.P. Berzins S.P. Heng T.S. et al (2005) Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 175: 2741–2753.
74. Takahashi K. Tanabe K. Ohnuki M. Narita M. Ichisaka T. Tomoda K. et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872.
75. Takahashi K. Yamanaka S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676.
76. Tateishi K. He J. Taranova O. Liang G. D'Alessio A.C. Zhang Y. (2008) Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem 283: 31601–31607.
77. Vandenbossche G.M. Bracke M.E. Cuvelier C.A. Bortier H.E. Mareel M.M. Remon J.P. (1993) Host reaction against empty alginate-polylysine microcapsules. Influence of preparation procedure. J Pharm Pharmacol 45: 115–120.
78. Verda L. Kim D.A. Ikehara S. Statkute L. Bronesky D. Petrenko Y. et al (2008) Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 26: 381–386.
79. Wernig M. Meissner A. Foreman R. Brambrink T. Ku M. Hochedlinger K. et al (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448: 318–324.
80. Wernig M. Zhao J.-P. Pruszak J. Hedlund E. Fu D. Soldner F. et al (2008) Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci 105: 5856–5861.
81. Wild S. Roglic G. Green A. Sicree R. King H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–1053.
82. Woltjen K. Michael I.P. Mohseni P. Desai R. Mileikovsky M. Hamalainen R. et al (2009) piggy Bac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458: 766–770.
83. Yamanaka S. (2009) A Fresh Look at iPS Cells. Cell 137: 13–17.
84. Yao S. Chen S. Clark J. Hao E. Beattie G.M. Hayek A. et al (2006) Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci U S A 103: 6907–6912.
85. Ye L. Chang J.C. Lin C. Sun X. Yu J. Kan Y.W. (2009) Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A 106: 9826–9830.
86. Yu J. Hu K. Smuga-Otto K. Tian S. Stewart R. Slukvin I.I. et al (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science 324: 797–801.
87. Yu J. Vodyanik M.A. Smuga-Otto K. Antosiewicz-Bourget J. Frane J.L. Tian S. et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.
88. Zhang D. Jiang W. Liu M. Sui X. Yin X. Chen S. et al (2009 a) Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res 19: 429–438.
89. Zhang J. Wilson G.F. Soerens A.G. Koonce C.H. Yu J. Palecek S.P. et al (2009 b) Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104: e30–e41.
90. Zhao X.-y. Li W. Lv Z. Liu L. Tong M. Hai T. et al (2009) iPS cells produce viable mice through tetraploid complementation. Nature 461: 86–90.
91. Zhou H. Wu S. Joo J.Y. Zhu S. Han D.W. Lin T. et al (2009) Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4: 381–384.
92. Zwi L. Caspi O. Arbel G. Huber I. Gepstein A. Park I.H. et al (2009) Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 120: 1513–1523.